BIOMAT Database Logo BIOMAT Database Logo

Inhibition of HIV-1 group M and O isolates by fusion inhibitors. 2005

Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
Department of Virology, University of Ulm, Albert Einstein Allee 11, 89081 Ulm, Germany.

We examined the susceptibility of HIV-1 group M and O isolates to the fusion inhibitors T-20 and T-1249. Unexpectedly, HIV-1 O isolates were as sensitive as group M viruses to inhibition by T-20 but were usually less susceptible to T-1249. Our data suggest that T-20 has broad antiretroviral activity and would be effective in individuals with HIV-1 O infection. However, polymorphisms in gp41 might affect the sensitivity of HIV-1 O to second-generation fusion inhibitors.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077560 Enfuvirtide A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS. DP 178,DP-178,DP178,Fuzeon,Pentafuside,Peptide T20,T20 Peptide,T20, Peptide
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015700 HIV Envelope Protein gp41 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV,HIV Transmembrane Protein gp41,HTLV-III gp41,env Protein gp41, HIV,gp41(HIV),gp41 Envelope Protein, HIV
D023581 HIV Fusion Inhibitors Inhibitors of the fusion of HIV to host cells, preventing viral entry. This includes compounds that block attachment of HIV ENVELOPE PROTEIN GP120 to CD4 RECEPTORS. Fusion Inhibitors, HIV,HIV Cell Fusion Inhibitor,HIV Entry Inhibitor,HIV Entry Inhibitors,HIV Fusion Inhibitor,HIV Fusion Protein Inhibitor,HIV Cell Fusion Inhibitors,HIV Fusion Protein Inhibitors,Entry Inhibitor, HIV,Entry Inhibitors, HIV,Fusion Inhibitor, HIV,Inhibitor, HIV Entry,Inhibitor, HIV Fusion
D024921 Drug Resistance, Multiple, Viral The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation. Drug Resistance, Extensive, Viral,Drug Resistance, Extensively, Viral,Extensive Antiviral Drug Resistance,Extensively Antiviral Drug Resistance,Multidrug Resistance, Viral,Multiple Antiviral Drug Resistance,Resistance, Viral Multidrug,Viral Multidrug Resistance,Viral Multidrug Resistances

Related Publications

Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
Inhibition of HIV-1 by fusion inhibitors.
January 2010, Current pharmaceutical design,
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.
July 2005, Journal of virology,
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
HIV-1 group M superinfection in an HIV-1 group O-infected patient.
December 2004, AIDS (London, England),
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
HIV infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections.
September 2004, AIDS research and human retroviruses,
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
HIV-1 group O and group M dual infection in Bénin.
March 1996, Lancet (London, England),
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
HIV-1 Group O Resistance Against Integrase Inhibitors.
September 2015, Journal of acquired immune deficiency syndromes (1999),
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
June 2015, AIDS (London, England),
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.
February 2011, Journal of acquired immune deficiency syndromes (1999),
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
Quantification of HIV-1 group M (subtypes A-G) and group O by the LCx HIV RNA quantitative assay.
September 2000, Journal of virological methods,
Raghavan Chinnadurai, and Jan Münch, and Matthias T Dittmar, and Frank Kirchhoff
Reactivity of a new HIV-1 group O third generation A-HIV-1/-2 assay with an unusual HIV-1 seroconversion panel and HIV-1 group O/group M subtyped samples.
December 1997, Journal of virological methods,
Copied contents to your clipboard!